Evaluation of diagnostic power of CgA determinations in neuroendocrine tumours (nets)

Arleta Malecha-Jędraszek; Helena Donica; Elżbieta Starosławska; Agata Burska; Beata Wojtysiak-Duma

doi:10.12923/

Authors

Arleta Malecha-Jędraszek Department of Biochemistry Diagnostics, Medical University of Lublin Author https://orcid.org/0000-0002-9104-9760
Helena Donica Department of Biochemistry Diagnostics, Medical University of Lublin Author https://orcid.org/0000-0003-0677-7825
Elżbieta Starosławska Oncological Centre of Lublin Region Author
Agata Burska Department of Biochemistry Diagnostics, Medical University of Lublin Author https://orcid.org/0000-0003-3321-9087
Beata Wojtysiak-Duma Department of Biochemistry Diagnostics, Medical University of Lublin Author https://orcid.org/0000-0002-2544-1385

DOI:

https://doi.org/10.12923/

Keywords:

chromogranin A, CgA, neuroendocrine tumors, NETs, diagnostic power

Abstract

Chromogranin A (CgA) is a 48 kDa hydrophilic acidic glycoprotein member of the granin family produced and stored together with biogenic amines and other peptide hormones in the secretory granules of the neuroendocrine cells, which are widespread in the whole organism and form the diffused endocrine system (DES). CgA is found in adrenal medulla, pancreatic islet cells, endocrine cells of the gastrointestinal tract and in sympathetic nervous system. CgA is physiologically released by exocytosis and may be detected in blood. Elevated circulating CgA levels have been demonstrated in serum or plasma of patients with various neuroendocrine tumors (NETs). Recent studies confirm that CgA is a useful marker for the diagnosis and follow-up of NETs. The aim of this study was to evaluate the diagnostic power of CgA determinations for the diagnosis of NETs. Analysis of the results of plasma CgA concentrations was performed in 41 patients with NETs. The control group was composed of healthy subjects (n=15). CgA plasma determinations were measured with the use of ELISA immunoenzymatic assay of commercially available kit Chromogranin A (DakoCytomation, Denmark). In order to investigate the diagnostic value of plasma CgA we plotted ROC (Receiver Operating Characteristic) curve and the area under the curve (AUC) was calculated. In our study, CgA plasma levels were statistically significantly higher (p<0.001) in patients with NETs compared to the control group. We calculated diagnostic sensitivity and specificity of CgA in NETs and positive and negative predictive values using the standard equations for the cut-off 18 U/l proposed by the manufacturer obtaining values of 71%, 87%, 93%, 52%, respectively. In conclusion, the DacoCytomation ELISA test for the determination of chromogranin A in plasma with the accepted cut-off value of 18 U/l that was used in this study has a good diagnostic power in detecting neuroendocrine tumors.

References

1. Baudin E., Bidart J.M., Bachelot A. et al.: Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann. Oncol., 12, S79, 2001.

2. Campana D., Nori F., Piscitelli L. et al.: Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?. J. Clin. Oncol., 25, 1967, 2007.

3. Kaltsas G.A., Besser G.M., Grossman A.B.: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev., 25, 458, 2004.

4. Nehar D., Lombard-Bohas C., Olivieri S. et al.: Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin. Endocrinol., 60, 644, 2004.

5. Nobels F.R.E., Kwekkeboom D., Bouillon R. et al.: Chromogranin A: its clinical value as marker of neuroendocrine tumors. Eur. J. Clin. Invest., 24, 431, 1998.

6. Peracchi M., Conte D., Gebbia C. et al.: Plasma Chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur. J. Endocrinol., 148, 39, 2003.

7. Seregni E., Ferrari L., Bajetta E. et al.: Clinical significance of blood CgA measurement in endocrine tumors. Ann. Oncol., 12, S69, 2001.

8. Stivanello M., Berruti A., Torta M. et al.: Circulating Chromogranin A in the assessment of patients with neuroendocrine tumors. A single institution experience. Ann. Oncol., 12, 573, 2001.

9. Stridsberg M., Eriksson B., Oberg K. et al.: A comparison between three commercial kits for Chromogranin A measurements. J. Endocrinol., 177, 337, 2003.

10. Taupenot L., Harper K.L., O’Connor D.T.: The chromogranin/secretogranin family. N. Eng. J. Med., 348, 1134, 2003.

11. Tomassetti P., Migliori M., Simoni P. et al.: Diagnostic value of plasma Chromogranin A in neuroendocrine tumors. Eur. J. Gastroenterol. Hepatol., 13, 55, 2001.

12. Zatelli M.C., Torta M., Leon A. et al.: Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr.-Relat. Cancer, 14, 473, 2007.

Evaluation of diagnostic power of CgA determinations in neuroendocrine tumours (net_s)

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

Issue

Section

License

sidebar

Language